Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $53.15 million
- Book Value:
- Revenue TTM:
- $10.16 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Curis Inc had its IPO on 2000-08-01 under the ticker symbol CRIS.
The company operates in the Healthcare sector and Biotechnology industry. Curis Inc has a staff strength of 51 employees.
Shares of Curis Inc opened at $0.54 at the start of the last trading session i.e. 2023-03-24.
The stocks traded within a range of $0.51 - $0.55, and closed at $0.54.
This is a +4.42% increase from the previous day's closing price.
A total volume of 228,697 shares were traded at the close of the day’s session.
In the last one week, shares of Curis Inc have slipped by -3.04%.
Curis Inc's Key Ratios
Curis Inc has a market cap of $53.15 million, indicating a price to book ratio of 1.3317 and a price to sales ratio of 5.019.
In the last 12-months Curis Inc’s revenue was $10.16 million with a gross profit of $-33372000 and an EBITDA of $-52787000. The EBITDA ratio measures Curis Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Curis Inc’s operating margin was -521.75% while its return on assets stood at -24.44% with a return of equity of -82.58%.
In Q4, Curis Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 7.9%.
Curis Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.57 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Curis Inc’s profitability.
Curis Inc stock is trading at a EV to sales ratio of 0.0082 and a EV to EBITDA ratio of 0.3712. Its price to sales ratio in the trailing 12-months stood at 5.019.
Curis Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $108.85 million
- Total Liabilities
- $10.01 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Curis Inc ended 2023 with $108.85 million in total assets and $0 in total liabilities. Its intangible assets were valued at $108.85 million while shareholder equity stood at $46.55 million.
Curis Inc ended 2023 with $0 in deferred long-term liabilities, $10.01 million in other current liabilities, 966000.00 in common stock, $-1148997000.00 in retained earnings and $8.98 million in goodwill. Its cash balance stood at $19.66 million and cash and short-term investments were $85.62 million. The company’s total short-term debt was $1,141,000 while long-term debt stood at $0.
Curis Inc’s total current assets stands at $92.12 million while long-term investments were $0 and short-term investments were $65.97 million. Its net receivables were $2.98 million compared to accounts payable of $3.19 million and inventory worth $0.
In 2023, Curis Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Curis Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Curis Inc stock is currently trading at $0.54 per share. It touched a 52-week high of $2.63 and a 52-week low of $2.63. Analysts tracking the stock have a 12-month average target price of $6.75.
Its 50-day moving average was $0.67 and 200-day moving average was $0.83 The short ratio stood at 7.15 indicating a short percent outstanding of 0%.
Around 592.4% of the company’s stock are held by insiders while 3291.8% are held by institutions.
Frequently Asked Questions About Curis Inc
Similar Industry Stocks (Biotechnology)
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.